- Home
- VRTX
as 02-21-2025 12:44pm EST
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 104.8B | IPO Year: | 1991 |
| Target Price: | $505.61 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 25 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $377.85 - $519.88 | Next Earning Date: | 02-10-2025 |
| Revenue: | $11,020,100,000 | Revenue Growth: | 11.66% |
| Revenue Growth (this year): | 9.62% | Revenue Growth (next year): | 9.25% |
Stock Insider Trading Activity of Vertex Pharmaceuticals Incorporated (VRTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ambrose Kristen | VRTX | SVP & Chief Accounting Officer | Feb 14 '25 | Sell | $455.06 | 671 | $305,345.26 | 10,798 | |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Feb 14 '25 | Sell | $455.06 | 244 | $111,034.64 | 67,695 | |
| Biller Jonathan | VRTX | EVP and Chief Legal Officer | Feb 14 '25 | Sell | $455.06 | 1,657 | $754,034.42 | 17,606 | |
| Ambrose Kristen | VRTX | SVP & Chief Accounting Officer | Feb 10 '25 | Sell | $459.83 | 1,376 | $632,726.08 | 10,798 | |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Feb 10 '25 | Sell | $459.83 | 310 | $142,547.30 | 67,695 | |
| Biller Jonathan | VRTX | EVP and Chief Legal Officer | Feb 10 '25 | Sell | $459.87 | 3,433 | $1,578,733.71 | 17,606 |
Latest Vertex Pharmaceuticals Incorporated News
VRTX Breaking Stock News: Dive into VRTX Ticker-Specific Updates for Smart Investing
Motley Fool
7 hours ago
2 No-Brainer Healthcare Stocks to Buy With $500 Right Now
Zacks
a day ago
GILD or VRTX: Which Is the Better Value Stock Right Now?
MT Newswires
a day ago
RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $408 From $407, Maintains Sector Perform Rating
Business Wire
3 days ago
Vertex to Participate in Upcoming March Investor Conferences
Motley Fool
4 days ago
3 Stocks That Could Trounce the Market in 2025
Motley Fool
6 days ago
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025
GuruFocus.com
7 days ago
CRISPR (CRSP) Upgraded to Outperform by Evercore, Price Target Raised to $99
Zacks
7 days ago
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Compare VRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRTX Vertex Pharmaceuticals Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.